GH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Guardant Health Inc (GH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and strategic acquisitions position it well for future growth. Despite some technical indicators being neutral, the long-term potential outweighs short-term fluctuations.
The MACD is below 0 and negatively contracting, indicating a bearish trend, while the RSI is neutral at 38.965. Moving averages are converging, and the stock is trading near its support level of 94.976, suggesting limited downside risk. However, no clear bullish signals are present.
Strong Q4 2025 revenue growth of 39% YoY, reaching $281.3 million.
Acquisition of MetaSight Diagnostics to bolster early cancer detection capabilities.
Positive analyst sentiment with multiple price target raises, including a high of $
Improved gross margin and narrowing net losses.
The stock's MACD and RSI indicate no clear bullish momentum.
Post-market price declined slightly by -0.38%.
No significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 39.37% YoY to $281.3 million, net income improved by 15.75% YoY to -$128.5 million, and EPS rose by 11.11% YoY to -1. Gross margin improved to 64.63%, up 5% YoY, indicating better operational efficiency.
Analysts are overwhelmingly positive, with multiple firms raising price targets recently. The highest target is $150, with most firms maintaining Buy or Overweight ratings, citing strong execution, strategic potential, and a robust 2026 outlook.
